CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Three-Pronged attack on tough stomach cancers
Disease control OngoingThis small, early-stage study is testing whether combining an immunotherapy drug (pembrolizumab) with chemotherapy and radiation can help control a type of stomach cancer that cannot be removed by surgery. The goal is to see if this three-part approach is safe and can shrink or e…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Scientists test new drug duo to fight tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Direct-Abdominal chemo tested for tough stomach cancers
Disease control OngoingThis early-stage study is testing whether delivering a chemotherapy drug called paclitaxel directly into the abdominal cavity is safe and tolerable for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The main goal is to find t…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control OngoingThis study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy drug (irinotecan) works better than the chemotherapy alone. It is for people with advanced stomach or esophageal junction cancer that has a specific genetic change (TP53 mutati…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC